Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03057977 · ClinicalTrials.gov registry record · Phase 3
EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)
A Phase 3 study of Heart Failure, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,730
- Enrollment target
- 20
- Study locations
NCT03057977: Completed Phase 3 study of Heart Failure, sponsored by Boehringer Ingelheim.
NCT03057977 is a Phase 3 study of Heart Failure that has completed, run by Boehringer Ingelheim. The registered enrollment target is 3,730 participants, above the 2,040-participant average among 397 other Heart Failure trials with a reported enrollment target (83% higher). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03057977, a Phase 3 study of Heart Failure, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,730 participants
- Enrollment target
- 20
- Study locations
Study Summary
The aim of the study is to investigate the safety and efficacy of empagliflozin versus placebo on top of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction.
Primary Outcome
Time to the first event of adjudicated cardiovascular (CV) death or adjudicated hospitalisation for heart failure (HHF). The incidence rate per 100 patient years (100 \* number of patients with event /time at risk \[years\]) is presented. With time at risk \[year\] calculated as: Sum of time at risk \[days\] over all patients in a treatment group / 365.25. Patients without a specific endpoint event were censored at the last date the patient was known to be free of the event or at the end of the
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Empagliflozin
Study Locations (20)
Florida
- Integrated Heart Care - Boca Raton
- Morton Plant Mease Health Care - Clearwater
- Nature Coast Clinical Research - Crystal River
- Avail Clinical Research, LLC - DeLand
- Holy Cross Hospital - Fort Lauderdale
- Integrative Research Associates - Fort Lauderdale
- Nature Coast Clinical Research - Inverness
- East Coast Institute for Research, LLC - Jacksonville
- Jacksonville Center for Clinical Research - Jacksonville
- Cardiovascular Research Center of South Florida - Miami
California
- La Mesa Cardiac Center - La Mesa
- Long Beach Center for Clinical Research - Long Beach
- VA Greater Los Angeles Healthcare System - Los Angeles
- Merced Vein and Vascular Center - Merced
- University of California Irvine - Orange
- Covigilant Research, LLC - Riverside
- University of California - Torrance
- Orange County Research Center - Tustin
- Blue Coast Cardiology - Vista
Colorado
- South Denver Cardiology Associates, PC - Littleton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,730 participants |
| Start Date | 2017-03-06 |
| Est. Completion | 2020-05-28 |
| Phase | Phase 3 |
What the finished NCT03057977 record still lists
NCT03057977 is an interventional study that assigns participants to a tested intervention. Its 3,730 participants enrollment target places it among the larger protocols in the corpus, above the 2,040-participant average among 397 other Heart Failure trials with a reported enrollment target (83% higher).
The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03057977 names 20 study sites across 3 states, led by Florida, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT03057977 about?
NCT03057977 is a clinical study titled "EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)". The aim of the study is to investigate the safety and efficacy of empagliflozin versus placebo on top of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction.
What is the current status of trial NCT03057977?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,730 participants. The study started on 2017-03-06. Estimated completion is 2020-05-28.
What conditions does trial NCT03057977 study?
This clinical trial studies the following conditions: Heart Failure.
What interventions are being tested in trial NCT03057977?
The interventions under investigation include: Placebo (DRUG), Empagliflozin (DRUG).
Who is sponsoring clinical trial NCT03057977?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03057977 being conducted?
This trial has 20 study locations across California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03057977's enrollment target sits among peer trials
3,730 31st of 397 higher than 367 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
RECRUITING · Phase 3
-
Home-based Cardiac Rehabilitation in Heart Failure
RECRUITING · Phase 3
-
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF)
RECRUITING · Phase 3
-
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
RECRUITING · Phase 3
-
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
RECRUITING · Phase 3
-
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06076304 · 3,720 participants · Phase 4
Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Acute Sinusitis
- NCT06172660 · 3,750 participants
Real-World Effectiveness of Perinatal RSV Immunoprophylaxis
- NCT06298253 · 3,750 participants · NA
Behavioral Economics to Implement a Traffic Light Nutrition Ranking System: Study 2
- NCT06401863 · 3,691 participants · NA
Shared Decision for Drug Interactions in Oral Anticoagulation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI